Mycoplasmas—the smallest known free-living organisms—are difficult-to-detect bacterial contaminants in mammalian cell cultures. In therapeutic applications, an undetected Mycoplasma contamination can negatively impact product quality and patient safety. Manufacturers following cGMP guidelines develop stringent risk mitigation plans to ensure early detection of Mycoplasmas to avoid costly manufacturing delay or remediation activities. For lot-release testing, many regulatory bodies require that all products derived from mammalian cell culture be tested for the presence of Mycoplasma.
Enhance your bioprocessing knowledge with educational content to help you understand issues, solve problems, and make solid decisions.
Deep dive into a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing.
Learn, evaluate, connect.
Connect with a Bioprocessing representative or request more info.
For Research Use Only. Not for use in diagnostic procedures.